Novel Real Time Polymerase Chain Reaction Approach for Rapid Detection of the Residual Escherichia coli Genomic DNA in Biopharmaceutical Products Establishment of Real Time Polymerase Chain Reaction to Detect Residual gDNA
T. Farivar, Babak Mamnoon, M. K. Arzenani, D. Ilghari
{"title":"Novel Real Time Polymerase Chain Reaction Approach for Rapid Detection of the Residual Escherichia coli Genomic DNA in Biopharmaceutical Products Establishment of Real Time Polymerase Chain Reaction to Detect Residual gDNA","authors":"T. Farivar, Babak Mamnoon, M. K. Arzenani, D. Ilghari","doi":"10.17795/BHS-26375","DOIUrl":null,"url":null,"abstract":"Background: Contamination of therapeutic recombinant proteins with residual host cell DNA must be controlled under the regulatory standards. Objectives: The current study established a new rapid, sensitive real time polymerase chain reaction (PCR) approach to measure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations. Materials and Methods: In this assay, a specific primer pair was utilized to amplify a 115 base pair sequence inside the E. coli 16S rRNA using SYBR Green Chemistry. This method enabled the authors to detect a very small quantity of the residual genomic DNA, as low as 0.8 pg, in the protein-based drugs. This method can, therefore, offer a dependable way to quantitatively analyze the major contaminant of biopharmaceutical products, the host cell DNA, during the manufacturing process. Results: SYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process. Conclusions: The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon manufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA.","PeriodicalId":8849,"journal":{"name":"Biotechnology and Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17795/BHS-26375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Contamination of therapeutic recombinant proteins with residual host cell DNA must be controlled under the regulatory standards. Objectives: The current study established a new rapid, sensitive real time polymerase chain reaction (PCR) approach to measure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations. Materials and Methods: In this assay, a specific primer pair was utilized to amplify a 115 base pair sequence inside the E. coli 16S rRNA using SYBR Green Chemistry. This method enabled the authors to detect a very small quantity of the residual genomic DNA, as low as 0.8 pg, in the protein-based drugs. This method can, therefore, offer a dependable way to quantitatively analyze the major contaminant of biopharmaceutical products, the host cell DNA, during the manufacturing process. Results: SYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process. Conclusions: The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon manufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA.
背景:治疗性重组蛋白与宿主细胞DNA残留的污染必须控制在监管标准之下。目的:建立一种新的快速、灵敏的实时聚合酶链反应(PCR)方法,可靠地测定重组链激酶和α干扰素制剂中残留的大肠杆菌(E. coli)宿主细胞基因组DNA。材料和方法:在本实验中,使用SYBR Green Chemistry,利用特定的引物对扩增大肠杆菌16S rRNA中的115碱基对序列。这种方法使作者能够在蛋白质药物中检测到非常少量的残留基因组DNA,低至0.8 pg。因此,该方法可以提供一种可靠的方法来定量分析生物制药产品在生产过程中的主要污染物——宿主细胞DNA。结果:SYBR Green PCR母品在生产过程中可能含有DNA污染源。结论:目前的研究数据显示,伊朗巴斯德研究所生产的链激酶和α干扰素中大肠杆菌宿主细胞DNA污染远低于FDA建议的安全限值。